CJC-1295 No DAC 5mg
Tetrasubstituted GHRH Analogue / Mod GRF 1-29
$35.00$25.00
Grade: Research Grade / Analytical Standard
Purity: ≥99% (HPLC Verified)
Format: Lyophilized (Freeze-Dried) Powder
Unit Size: 5 mg
Product Overview
CJC-1295 No DAC 5mg (also known as Mod GRF 1-29) is a synthetic 29-amino acid tetrasubstituted peptide analogue of naturally occurring Growth Hormone-Releasing Hormone (GHRH). Modified at positions 2, 8, 15, and 27 (D-Ala2, Gln8, Ala15, Leu27), this compound resists rapid enzymatic cleavage by dipeptidyl peptidase-4 (DPP-IV), significantly enhancing its biological half-life compared to native Sermorelin while preserving physiological pulsatile signaling.
Unlike versions containing the Drug Affinity Complex (DAC), CJC-1295 No DAC does not permanently bind to plasma albumin. This allows research facilities to evaluate short, controlled, and physiological growth hormone (GH) and IGF-1 release pulses by targeting pituitary GHRH receptors without causing baseline hormone desensitization.
Key Research Features & Highlights
Tetrasubstituted Stability: Engineered modifications prevent rapid DPP-IV enzymatic breakdown, offering superior structural stability and prolonged receptor binding over unmodified GRF 1-29.
Pulsatile GH Signaling: Delivers sharp, transient growth hormone release pulses that closely mimic native circadian pituitary discharge patterns.
Pituitary Somatotroph Binding: Acts as a direct, highly selective agonist at the GHRH receptor to stimulate endogenous GH synthesis and secretion.
Downstream IGF-1 Axis Upregulation: Serves as a primary reference tool for studying systemic Insulin-like Growth Factor 1 elevation, nitrogen retention, and cellular anabolic repair.
Analytical Grade Purity (≥99%): Independently validated via High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS) to guarantee high batch-to-batch repeatability.
Primary Applications in Laboratory Research
Pituitary Receptor Activation & Secretagogue Kinetics: Investigating GHRH receptor signaling cascades, intracellular cAMP accumulation, and growth hormone secretion dynamics.
Protein Translation & Anabolic Pathways: Studying Akt/mTOR pathway activation, amino acid uptake, and cellular hypertrophy in muscle tissue models.
Adipocyte Lipolysis & Metabolic Regulation: Researching lipid clearance, visceral adiposity reduction, and basal energy expenditure modulation.
Connective Tissue & Extracellular Matrix Dynamics: Evaluating collagen synthesis, tendon and ligament repair kinetics, and bone mineral density signaling.
Product Specifications
Attribute | Specification |
Active Compound | CJC-1295 No DAC (Mod GRF 1-29) |
Net Quantity | 5 mg |
Form | Lyophilized White Powder |
CAS Number | 863288-34-0 |
Molecular Mass | ~3367.90 g/mol |
Sequence | Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2 |
Purity Standard | ≥99% (HPLC verified) |
Solubility | Soluble in Bacteriostatic Water or Sterile Deionized Water |
Storage & Handling Protocols
Unreconstituted (Lyophilized): Store frozen at or below -20°C in a dry, dark environment protected from heat, light, and humidity.
Reconstituted Solution: Maintain at 2°C – 8°C following dilution with sterile solvent (e.g., Bacteriostatic Water) and utilize within 30 days. Avoid repeated freeze-thaw cycles.
Mandatory Research & Legal Disclaimer
FOR LABORATORY RESEARCH USE ONLY. This compound is distributed exclusively for in vitro scientific research, educational, and analytical laboratory applications. It is not approved for human or animal consumption, medical therapy, diagnostic procedures, or commercial drug formulation.